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Implantation Techniques for the TCI HeartMate 
Left Ventricular Assist Systems 
James P. Slater, Matthew Williams, and Mehmet C. Oz 
Left ventricular assist device (LVAD) support is an 
increasingly used option for patients with end-stage 
heart disease who require cardiac replacement but 
become hemodynamically unstable despite maximal 
medical therapy; these patients are unlikely to survive 
until a donor organ becomes available.' Broadening 
clinical experience with LVADs as bridge-to-transplan- 
tation should guide the development of permanently 
implanted devices to be used as destination cardiac 
replacement therapy. One of the two Food and Drug 
Administration-approved, long-term implantable sys- 
tems is the TCI HeartMate (Thermocardio Systems, 
Woburn, MA). The HeartMate is a pulsatile blood 
pump that is available in pneumatically driven or 
electrically powered versions (Fig I). The titanium shell 
houses a flexible polyurethane diaphragm bonded to a 
rigid pusher plate. To date, nearly 2,000 HeartMate 
systems have been implanted worldwide, representing 
484 cumulative patient-years of support and a success- 
to-transplantation rate of approximately 75% .' One of 
several unique design features of this device is textured 
surfaces that promote the formation of a neointimal 
lining. This nonthrombogenic biological lining becomes 
the blood-device interface, precluding the need for 
long-term systemic anticoagulation. Clinically, this trans- 
lates to the lowest reported thromboembolic complica- 
tion rate for any LVAD system. 
Potential LVAD recipients must be screened carefully 
for up-to-the-minute hernodynamic performance, end 
organ function, and evaluation of survival limiting 
comorbidities. Exclusionary criteria include those tradi- 
tionally used for cardiac transplantation screening: 
chronic renal failure, severe peripheral and cerebrovas- 
cular disease, hepatic failure, pulmonary insufficiency, 
metastatic malignancy, blood dyscrasias, and uncontrol- 
lable infe~t ion .~  Ideal candidates are those who have 
been previously listed for cardiac transplantation with 
worsening hemodynamic function despite increasing 
inotropic support and preserved end-organ function. 
Postcardiotomy shock patients make up another cohort 
of potential LVAD recipients. Risk factors adversely 
affecting survival in this group include unsuccessful 
operation, perioperative myocardial infarction, biven- 
tricular failure, and advanced age. 
Perioperative management issues include bleeding, 
right ventricular failure, postbypass shock, and blood 
product administration. Bleeding complications have 
been consistently reported, and extensive blood loss 
and subsequent blood product administration may 
increase pulmonary vascular resistance, which in turn 
exacerbates right-sided circulatory failure. Aprotinin 
has been successful in decreasing postoperative bleed- 
ing and associated  complication^.^ 
Right-sided circulatory failure occurs in more than 
20% of patients requiring LVADS.~ Perioperative inotro- 
pic support is targeted toward the right side of the 
heart, with the objectives of minimizing pulmonary 
vascular resistance and maximizing right ventricular 
performance. Inhaled nitric oxide has been an impor- 
tant addition to our arsenal and has resulted in a 
significant decrease in the need for right ventricular 
assist support.6 
Late postoperative management strategies frequently 
must address problems of ventricular arrhythmias, 
infection, and thromboembolism. Malignant ventricu- 
lar arrhythmias are remarkably well tolerated once the 
transient increase in pulmonary vascular resistance 
that accompanies implantation  resolve^.^ Often, identi- 
fication of these arrhythmias is made on routine exami- 
nations and is not related to hemodynamic or clinically 
apparent changes. Arrhythmias should be treated by 
conventional therapies, cardioversion or pharmacologi- 
cally, with urgency dictated by hemodynamic stability. 
Non-device-related infections remain common in the 
LVAD population awaiting transplantation. Although 
these frequent infections are associated with increased 
time to transplant, there is no difference in survival to 
transplant in patients who experience infections com- 
pared with those who do not. Two important subsets are 
those patients who develop either driveline/pocket infec- 
tions and those who develop infection within the device 
itself, so-called LVAD endocarditis. These are serious 
life-threatening infections in which the only chance for 
successful treatment is prompt device explant.8 
Thromboembolism has traditionally been the Achil- 
les' heel of artificial cardiac support. Thromboembolic 
rates in excess of 30% have been reported with some 
devices despite the need for full anticoagulation. The 
TCI HeartMate has a reported thromboembolic rate of 
1.3% without the need for systemic anticoagulation.9 
Unique design features, including textured surfaces, a 
short inflow cannula, use of bioprosthetic valves, and a 
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wandering vortex flow pattern, are credited for this 
important advance. 
During the past decade, technological advances in 
LVAD design, biomaterials, and miniturization have 
evolved to the point at which bulky external consoles 
have been excluded. Near fully implantable, wearable 
LVAD systems have performed increasingly well in the 
bridge-to-transplant era, with transplantation rates of 
74% being reported. As valuable clinical experience 
continues to be accrued and technological advances 
make fully implantable devices a reality, the objective 
of long-term artificial support for end-stage cardiomy- 
opathy becomes increasingly obtainable. 
Operation Overview 
The operation is begun by making an incision from the 
sternal notch to the umbilicus. A standard midline 
sternotomy is performed, and a pericardial well is created. 
Aortic cannulation sutures are placed at this time in the 
advent that it is necessary to institute cardiopulmonary 
bypass emergently. The abdominal fascia is divided in 
the midline to expose the preperitoneal fat. A preperito- 
neal pocket is then created for the body of the device. 
Once the pocket is completed, the device is brought onto 
the field, and a subcutaneous tunnel is created through 
which the device driveline is delivered. Whenever 
clinical circumstances allow, the above-described steps 
are performed before heparinization to avoid excessive 
bleeding postoperatively. If the patient is hemodynami- 
cally unstable, then cardiopulmonary bypass can be 
initiated before creation of the pocket. 
Cardiopulmonary bypass is initiated after pocket and 
driveline creation. Standard aortic and dual-stage right 
atrial cannulation is used. Because the right atrium is 
frequently distended, we use a bovine pericardial pled- 
get-reinforced atrial purse string. We prefer to place 
the cannula and initiate cardiopulmonary to decom- 
press the right atrium before tightening the purse string 
to avoid injury to the atrial appendage. Immediately 
after institution of cardiopulmonary bypass, a stab 
wound is made in the left ventricular apex through 
which a vent is placed to allow for decompression of the 
left ventricle. With the heart in its native position, 
return through the apical vent is measured to determine 
the presence of aortic insufficiency. A volume of greater 
than 1.5 L/min is considered to be suggestive of aortic 
insufficiency and may require surgical intervention. We 
do not routinely cross-clamp the aorta or institute 
cardioplegic arrest unless the aortic valve requires 
repair. 
Once cardiopulmonary bypass has been initiated, the 
left ventricular apex is cored, using the left ventricular 
vent as a guide. The inflow ring is sewn into place using 
interrupted, pledgeted, horizontal, mattress-style su- 
tures. An opening is then made in the diaphragm 
through which the inflow cannula of the device is 
passed. The inflow cannula is seated into the left 
ventricle via the attached sewing ring and fastened into 
place. Next, a partial-occluding clamp is placed on the 
ascending aorta, an aortotomy is created, and the out- 
flow graft is anastomosed in an end-to-side fashion. The 
outflow graft is then connected to the device, and, after 
a period of deairing, device support is initiated, and 
cardiopulmonary bypass is weaned. Heparin is re- 
versed, and the patient is decannulated and closed once 
hemostasis is achieved. 
The success of LVAD implantation is frequently 
related to the avoidance of postoperative hemorrhage. 
Patients on the TCI HeartMate device support do not 
require anticoagulation therapies; however, the blood- 
device surface interaction does result in a fibrinolytic 
state that manifests early on as a profound coagulopa- 
thy. Although we believe this fibrinolytic state to be 
beneficial in the long-term to protect against thrombo- 
embolic events, in the immediate postoperative period, 
it can result in significant hemorrhage. In addition, 
patients in the heart failure population tend to have 
congestion-related hepatic dysfunctian that contributes 
to an even more profound coagulopathy. Throughout 
the detailed steps that follow, we will highlight strategies 
that we use to avoid postoperative hemorrhage. 
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SURGICAL TECHNIQUE 
1 A midline incision from the sternal notch to the 
umbilicus is used. The midline sternotomy is completed, 
and the pericardial well is created to afford immediate 
access to the heart should the patient become unstable. 
Aortic purse-string sutures are also placed at  this time in 
the event that cardiopulmonary bypass must be initiated 
emergently. Once these maneuvers have been completed, 
the abdominal incision is completed by dividing the 
abdominal fascia in the midline to expose the preperito- 
neal layer. 
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2 The preperitoneal pocket is fashioned by upward retraction on the abdominal 
fascia and using electrocautery on a low setting to separate the fascia from the 
preperitoneal tissues (A). We work in a cephalad direction first to expose the 
underside of the diaphragm. Care is taken to identify the phrenic vessels and either 
avoid them or ligate them deliberately. As this flap is raised laterally, the preperito- 
neal tissue becomes exceedingly thin. At this point, we change planes and allow the 
fascia to make up the floor of the preperitoneal pocket. We then work in a caudad 
direction until the pocket reaches its final dimensions extending from under the costal 
margin to the umbilicus, with enough lateral width to accommodate the device. A 
device model is kept on the field to confirm pocket size. 
A small amount of dissection is required along the right fascia1 edge (B). Similar to 
the left-sided dissection, the right fascia is retracted upward, and only enough is freed 
to allow for easy, tensionless closure. The area under the right costal margin (space of 
Larrei) is dissected using electrocautery to allow room for the outflow graft to seat 
without impingement. Terminal branches of the right, internal, mammary artery may 
be divided during this dissection. These branches must be ligated deliberately to avoid 
postoperative bleeding. 
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3 The only external connection between the HeartMate and the controller is via the 
driveline. The driveline originates at the device base offset to the left and, after 
passing inferior to the umbilicus, exits the patient’s right side at approximately one 
third of the distance between the umbilicus and the right costal margin. We have 
found that this gentle upward curve facilitates patient mobility. The driveline is 
passed by making a small circular incision at the exit site (similar to an ostomy site). 
This incision need only be big enough to accept the driveline tunneler. The tunneler is 
introduced into the subcutaneous layer and advanced so that it passes just beneath 
the umbilicus. A downward motion then forces the tunneler superiorly, and the tip 
can be inserted into the pocket. The driveline cap is then threaded onto the tunneler, 
and the entire driveline is delivered through the tunnel and out the incision. The 
incision can be enlarged as necessary to allow the driveline to pass. Too large an 
incision will result in failure of the exit site to fibrose around the driveline, which in 
turn can be a source of persistent drainage and potential infection. 
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4 The inflow cannula of the device enters the left ventricle through an opening that 
has been cored from the ventricular apex. A circular coring knife is provided with the 
device implantation kit. The apex of the ventricle has previously been located and 
incised to allow passage of the left ventricular vent. When the heart is oriented so that 
the apex is pointed upward, gentle finger-tip palpation shows a soft spot surrounded 
by thickened muscle. This soft spot is the ventricular apex. An 11 blade is used to 
incise the apex at the time of vent placement. At the time of coring, the vent is removed 
and replaced by a Foley catheter (C. R. Bard, Inc, Covington, GA), which has been 
passed through the coring knife (A). The Foley catheter balloon is filled with 
approximately 5 mL of saline. The gentle traction on the Foley catheter provides 
countertraction to the advancing coring knife. When the ventricular wall has been 
completely incised, the knife passes freely into the ventricle (B). The catheter and 
coring knife are removed as a unit, and the core is inspected for completeness (C). In 
addition, the left ventricle is inspected for thrombus, retained core, or myocardial 
tissue that may obstruct inflow to the device. Great care must be taken to angle the 
coring knife away from the septum to avoid both septa1 injury and to prevent the 
inflow cannula from resting against the septum and obstructing inflow. 
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4 (continued) 
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5 The inflow cannula of the device is held in place in the left ventricular apex by 
the sewing ring, a silastic tube with an attached Teflon ring. The sewing ring is 
anastomosed to the left ventricle using a pledgeted coated, braided, polyester 
cardiovascular suture placed in interrupted horizontal mattress fashion (A). Bites are 
taken at some distance from the core edge and pass nearly full thickness before exiting 
the epicardial surface. It is important not to exit the suture within the cored edge, 
because this will draw the sewing ring into the left ventricle. An alternative method is 
to pass the needle full thickness into the ventricle and exit it full thickness, mattress 
style, through the epicardial edge. This guarantees an appropriately deep bite. We 
place four evenly spaced sutures initially then divide the remaining area with an 
additional eight sutures. Analogous to valve surgery, all distance is made within each 
suture, rather than between sutures. The sewing ring is tied into place (B). Suture 
tension should be just enough to bunch the myocardium. If the sutures are 
overtightened, the fragde myocardium will tear, resulting in suture-line disruption. 
The suture line may be tested by gently occluding the silastic ring and allowing the 
heart to be filled with blood from the bypass machine. Leaking areas can be repaired 
with interrupted, pledgeted sutures. 
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6 The inflow cannula is passed into the left ventricular apex through the sewing 
ring. The inflow cannula first must cross the diaphragm either through an opening 
created using electrocautery or by dividing the most medial portion of the diaphragm. 
Attention to hemostasis is essential. The surgeon grasps the heart with his left hand as 
close to its base as possible and rotates it toward the patient’s left. The tip of the inflow 
cannula is controlled with the thumb and forefinger of the right hand and is also 
rotated to the patient’s left. The inflow cannula is then inserted through the silastic 
ring and worked into the ventricle. The assistant aides the process by placing 
hemostats on either side of the silastic ring and applying gentle downward traction 
until the cannula is well seated. There is a perceptible feeling when the cannula is 
appropriately engaged. We then secure the cannula in three places, first with a heavy 
silk tie, then with a sterile band applied with a banding gun, and last with an 
additional heavy silk tie. These not only hold the cannula in place, but also prevent 
air from being entrained into the device. The entire connection is also packed with 
thrombin-soaked gel foam and sponges to prevent air from entering via needle holes. 
Once the connection is completed, blood in the left ventricle fills the device and 
passively flows from the outflow arm. Placing volume in the patient should result in 
significant flow from the device. Absence of flow and a distended left ventricle suggest 
inflow occlusion, which should be addressed before proceeding. 
340 SLATER ET AL 
7 The outflow graft is anastomosed to the ascending aorta in an end-to-side 
fashion. This anastomosis should be positioned with consideration for the next 
operation, which is likely to be cardiac transplantation. Ideally, the graft will be 
positioned high enough to allow for aortic-aortic anastomosis at the time of 
transplant, but low enough to allow for easy placement of an aortic cross-clamp. 
Measurement of the graft length is critical. If the graft is too long, kinking can occur, 
which may result in outflow obstruction. Previously, we would perform this 
anastomosis using a partial occlusion clamp before initiation of cardiopulmonary 
bypass. However, this technique requires estimating the length of the graft. If the 
inflow portion of the operation has already been completed, then the graft can be 
measured directly and overestimation is avoided. 
The TCI HeartMate uses a Dacron outflow graft, which is preclotted at the 
beginning of the operation by heating it after application of a layer of the patient’s 
nonheparinized blood. Albumin can be used as a substitute. There are advantages 
and disadvantages to the use of Dacron (Dupont, Wilmington, DE). The stiffness of 
the preclotted graft is often in contradistinction to the soft, nondiseased aorta. The 
resulting needle holes can result in a significant bleeding problem postoperatively. 
Several strategies that we use to minimize bleeding are removal of an ellipse of aortic 
tissue, including use of a 4.0-mm punch in each corner; reinforcement with bovine 
pericardial strips for the entire anastomosis; and meticulous technique with great 
care not to overtighten during anastomotic creation. A benefit of Dacron is that it does 
not promote adhesions and, therefore, is easily separated from surrounding tissues at 
the time of explant. On occasion, we have chosen to use a more pliable graft to sew to 
the aorta, and then created a graft-to-graft anastomosis. 
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8 Deairing is the next crucial step in the process of implantation. Once the 
anastomosis is completed, we place a clamp on the graft and remove the partial 
occlusion clamp to displace as much air as possible. The outflow graft is then attached 
to the device loosely so that blood flows easily through the connector and air can be 
evacuated; in addition, a deairing needle is placed at the high point of the graft. 
Volume is left in the patient, the lungs are inflated, and the device is hand-pumped 
against the clamp to remove the remaining air. The clamp is removed and hand- 
pumping continues while transesophageal echocardiography is used to monitor the 
ascending aorta. If large amounts of air are seen being ejected into the ascending 
aorta, the clamp is reapplied to the graft and deairing maneuvers are repeated. If 
little or no air is seen, then hand-pumping is continued to keep the left ventricle from 
distending. 
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9 Once adequately deaired, the outflow graft connection is tightened. We reinforce 
all connections with a bovine pericardial wrap to maintain orientation and prevent 
bleeding. Both inflow and outflow anastomoses are packed with gel foam. All surgical 
sites are inspected for bleeding, and repairs are performed as needed. As the patient 
rewarms, we place atrial and ventricular wires and both anterior and posterior 
pericardial chest tubes and pleural chest tubes if necessary. A Jackson-Pratt drain is 
left in the LVAD pocket. 
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10 Inotropic support is targeted to the maintenance of right heart function. 
Typically, dobutamine and milrinone are used, along with an agent for afterload. If 
right-sided pressures are high, we frequently use inhaled nitric oxide. Hand-pumping 
is used to maintain LVAD flow, whereas pump flow is decreased to 2 Umin. The 
controller is then connected, and autonomous LVAD flow is initiated in a fixed-rate 
mode as cardiopulmonary bypass is terminated. The patient is carefully monitored 
for increasing pulmonary pressures, distended right or left ventricles, and systemic 
arterial pressure. If stable, the device is switched to automatic mode and is allowed to 
assume a maximal cardiac output. Protamine is then administered for full heparin 
reversal, and, after hemostasis has been achieved, closure is performed. Chest tubes 
are placed in pleural spaces as needed and in the anterior and posterior pericardium. 
The LVAD pocket is drained with a no. 10 Jackson-Pratt. The sternum and abdomen 
are closed in standard fashions. In smaller patients, a Gortex (W. L. Gore, Flagstaff, 
AZ) patch may be useful in approximating the abdominal fascia. 
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